NYSE · CRL · Diagnostics & Research
Charles River Laboratories Inte (CRL) stock analysis
- CRL gained 21.0% over the past month versus 0.0% for the S&P 500, ranking 8th of 497 S&P 500 stocks.
- Over 12 months it returned +87.3%, 71.5 points ahead of the S&P 500, and trades 0.0% below its 52-week high.
- In the last 30 days 6 analysts raised earnings estimates and 3 cut; forward EPS moved +0.6% (+3.5% over 90 days).
- It sits in the Research & clinical outsourcing segment of the Medtech, Diagnostics & Care, where the 1-month median return is +11.7%.
- The daily chart reads Intermediate uptrend · Breakout retest (since Oct 20, 2026).
One-year price with 50- and 200-day averages
Performance vs the market
Total price return against the S&P 500 (SPY) and the median of US stocks in the same sector.
Chart structure
Read by our daily-bar structure engine from swing highs, swing lows and moving averages.
Holding since Oct 20, 2026
- Close above EMA20 above EMA50
- EMA50 rose over the last ten sessions
39 occurrences in 10 years. The median move over the next 20 sessions was +1.9%, positive 54% of the time, against +1.5% for any day in the same period.
Analyst earnings revisions
Changes to the consensus forward-EPS estimate. Rising estimates mean analysts see more profit ahead.
14 analysts cover the stock
Where it sits in the supply chain
Medtech, Diagnostics & Care · Tools & research
Drug research, clinical and data services form a research-services branch.
Figures are each company's 1-month return; the segment shows its median · Doubler daily batch · company chain maps
Risk profile
Track this stock every day
Hub adds the daily brief, StockFlow factor flow, trade plans and alerts for your watchlist.